NDLI: Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Please wait, while we are loading the content...

Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

The study of novel DNA vaccines against tuberculosis: Induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis

Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy

Applications and challenges of multivalent recombinant vaccines.

Murine infection models for vaccine development: the malaria example.

Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease.

Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus.

Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197

Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae.

Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.

Are vaccination models suitable to determine whether probiotics have beneficial health effects in the general population?

Epitope-specific immune recognition of the nontypeable Haemophilus influenzae outer membrane protein 26.

Progress in the elimination of measles and congenital rubella in Central Italy.

Influenza epidemiology in Italy two years after the 2009–2010 pandemic: Need to improve vaccination coverage

Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: evaluation of immunogenicity, cross-protection, safety and tolerability.

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children.

Are risk factors associated with invasive pneumococcal disease according to different serotypes?

Immunotherapy in new pre-clinical models of HPV-associated oral cancers

A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge

Epidemiology of HBV S-gene mutants in the Liguria Region, Italy: Implications for surveillance and detection of new escape variants.

Neisseria lactamica antigens complexed with a novel cationic adjuvant.

Results of the rubella elimination program in Catalonia (Spain), 2002-2011.

Surveillance of influenza viruses in the post-pandemic era (2010-2012) in Northern Italy.

Surveillance of hospitalized and outpatient cases of pertussis in Catalonia from 2003 to 2009.

Epidemiology of two large measles virus outbreaks in Catalonia: what a difference the month of administration of the first dose of vaccine makes.

Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines.

Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.

Effectiveness of the WC/rBS oral cholera vaccine in the prevention of traveler's diarrhea: a prospective cohort study.

A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination.

Influenza sentinel surveillance network: a public health-primary care collaborative action to assess influenza A(H1N1)pmd09 in Catalonia, Spain.

Eighth World Congress on Vaccines, Immunisation and Immunotherapy.

Letter from the editor.

Year: 2013 Volume: 9 Issue: 2

Year: 2013 Volume: 9 Issue: 1

Year: 2012 Volume: 8

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Boccalini, Sara Bechini, Angela Levi, Miriam Tiscione, Emila Gasparini, Roberto Bonanni, Paolo
Spatial Coverage	Italy
Description	Country affiliation: Italy Author Affiliation: Boccalini S ( Department of Health Sciences)
Abstract	Community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) are very relevant pathologies among elderly people (≥ 65 y old), with a consequent high disease burden. Immunization with the 23-valent pneumococcal polysaccharide vaccine (PPV23) has been differently implemented in the Italian regions in the past years, reaching overall low coverage rates even in those with medical indications. In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) became available and recommended in the universal Italian infant immunization program. Since October 2012, indications for use of PCV13 were extended to subjects ≥ 50 y to prevent invasive pneumococcal diseases. The Italian decision makers should now revise regional indications for the prevention of pneumococcal diseases in the elderly. Pharmaco-economic analyses represent a useful tool to value the feasibility of new immunization programs and their sustainability. Therefore, an ad hoc population model was developed in order to value the clinical and economic impact of an adult pneumococcal vaccination program in Italy. Particularly, different immunization scenarios were modeled: vaccination of 65 y-olds (1 cohort strategy), simultaneous vaccination of people aged 65 and 70 y (double cohort strategy) and, lastly, immunization of people aged 65, 70 and 75 y (triple cohort strategy), thus leading to the vaccination of 5, 10 and 15 cohorts during the 5 y of the program. In addition, the administration of a PPV23 dose one year after PCV13 was evaluated, in order to verify the economic impact of the supplemental serotype coverage in elderly people. The mathematical model valued the clinical impact of PCV13 vaccination on the number of bacteraemic pneumococcal pneumonia (BPP) and pneumococcal meningitis (PM) cases, and related hospitalizations and deaths. Although PCV13 is not yet formally indicated for the prevention of pneumococcal CAP by the European Medicine Agency (differently from FDA, whose indications include all pneumococcal diseases in subjects ≥ 50 y), the model calculated also the possible impact of vaccination on CAP cases (non-bacteraemic), considering the rate of this disease due to S. pneumoniae. The results of the analysis show that, in Italy, an age-based PCV13 vaccination program in elderly people is cost-effective from the payer perspective, with costs per QALY ranging from 17,000 to 22,000 Euro, according to the adopted vaccination strategy. The subsequent PPV23 offer results in an increment of costs per QALY (from 21,000 to 28,000 Euro, according to the vaccination strategy adopted). Pneumococcal vaccination using the conjugate vaccine turned out to be already favorable in the second year of implementation, with incremental costs per QALY comparable to those of other already adopted prevention activities in Italy (for instance, universal HPV vaccination of 12 y-old girls), with further benefits obtained when extending the study period beyond the 5-y horizon of our analysis.
File Format	HTM / HTML
ISSN	21645515
e-ISSN	2164554X
Journal	Human Vaccines & Immunotherapeutics
Issue Number	3
Volume Number	9
Language	English
Publisher	Taylor & Francis
Publisher Date	2013-03-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Immunology Discipline Therapeutics Bacteremia Prevention & Control Meningitis, Pneumococcal Pneumococcal Vaccines Immunology Pneumonia, Pneumococcal Vaccination Utilization Animals Epidemiology Mortality Cost-benefit Analysis Hospitalization Statistics & Numerical Data Models, Theoretical Administration & Dosage Complications Survival Analysis
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.

Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

HPV vaccination in boys and men.

A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.

Pneumococcus, illetve bármely kórokú pneumonia, meningitis és septikaemia miatti hospitalizáció és halálozás Magyarországon. Egy retrospektív értékelés eredménye (2006-2011).

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies.

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies.

Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.

The economic burden of childhood invasive pneumococcal diseases and pneumonia in Taiwan: Implications for a pneumococcal vaccination program.

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Similar Documents

Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.

Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

HPV vaccination in boys and men.

A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.

Pneumococcus, illetve bármely kórokú pneumonia, meningitis és septikaemia miatti hospitalizáció és halálozás Magyarországon. Egy retrospektív értékelés eredménye (2006-2011).

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies.

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies.

Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.

The economic burden of childhood invasive pneumococcal diseases and pneumonia in Taiwan: Implications for a pneumococcal vaccination program.

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.